Alpha Cognition ACOG
NASDAQ ACOG
$8.58 -0.03 (-0.35%)
At close: Oct 21, 2026 · 4:00 PM EDT

Alpha Cognition (ACOG) Free Cash Flow (2023 - 2025)

Updated

Alpha Cognition's Free Cash Flow came in at -$7.05 million for Q4 2025, compared with -$2.3 million a year earlier.

Analysis

Alpha Cognition (ACOG) Free Cash Flow (2023 - 2025) Analysis & Trends

For FY2025, Alpha Cognition's Free Cash Flow was -$20.67 million.

  • Going back by year, Free Cash Flow was -$7.78 million in FY2024 and -$8.8 million in FY2023.
  • The Q4 2025 figure represents the lowest quarterly Free Cash Flow in data going back to Q3 2023.
  • Business Quant data shows ACOG's Free Cash Flow at -$5.36 million (Q3 2025), -$6.15 million (Q2 2025) and -$2.11 million (Q1 2025) in the three quarters before Q4 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) FCF (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn 7.76 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn 7.30 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn 3.11 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn 4.48 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn 5.56 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn 1.01 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn 3.49 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn 3.43 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn 302.00 Mn
10 Alpha Cognition 187.26 Mn 5.02 Mn 5.70 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 -7.05 Mn
Sep 30, 2025 -5.36 Mn
Jun 30, 2025 -6.15 Mn
Mar 31, 2025 -2.11 Mn
Dec 31, 2024 -2.30 Mn
Sep 30, 2024 -1.58 Mn
Jun 30, 2024 -1.40 Mn
Mar 31, 2024 -2.47 Mn
Dec 31, 2023 -2.03 Mn
Sep 30, 2023 -1.60 Mn
API Access

Alpha Cognition Free Cash Flow API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=free-cash-flow&ticker=ACOG&period=max&api_key=YOUR_API_KEY